SOT-102 is under clinical development by SOTIO Biotech and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SOT-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SOT-102 overview
SON-102 is under development for the treatment of gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ), metastatic pancreatic adenocarcinoma, liver cancer, colon cancer and lung adenocarcinomas. The drug candidate is a monoclonal antibody conjugate developed based on Transpo-mAb antibody platform, sortase-enzyme mediated antibody conjugation technology (site-specific SMAC) and ultra-potent anthracycline based toxin platform. It acts by targeting CLDN 18.2. It is administered through intravenous route.
SOTIO Biotech overview
SOTIO Biotech (Sotio), a subsidiary of PPF Group NV, is a biotechnology company that develops immunotherapies for the treatment of cancer. It is also evaluating IL-15, superagonist based programs to develop immunotherapies in oncology. Sotio utilizes its proprietary BOXR cell therapy platform to design and develop engineered T cells by identifying novel bolt-on transgenes in the solid tumor microenvironment. The company is investigating SOT101, a monotherapy in combination with pembrolizumab targeting metastatic solid tumor; and BOXR1030, CART T cell therapy against hepatocellular carcinoma and squamous cell carcinoma. The company operates research laboratories in Prague, Czech Republic; and Cambridge, Massachusetts, the US. Sotio is headquartered in Prague, North Bohemian, Czech Republic.
For a complete picture of SOT-102’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
